Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CXCR4 | P61073 | 4/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | CCR2 | P41597 | 1/20 | 0.34 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3096045 | 0.83 | POLB (0.33) | SMN1; SMN2POLBHSD17B10CXCR4SIGMAR1 | |
| SCHEMBL20459374 | 0.78 | — | — | |
| SCHEMBL25668133 | 0.78 | — | — | |
| SCHEMBL20980235 | 0.78 | — | — | |
| SCHEMBL150591 | 0.73 | — | — | |
| SCHEMBL3537892 | 0.73 | — | — | |
| SCHEMBL24079207 | 0.72 | CHRM5 (0.44) | SMN1; SMN2POLBHSD17B10CXCR4SIGMAR1 | |
| SCHEMBL10724711 | 0.72 | HSD17B10 (0.38) | SMN1; SMN2POLBHSD17B10CXCR4SIGMAR1 | |
| SCHEMBL24532104 | 0.72 | SIGMAR1 (0.41) | SMN1; SMN2POLBHSD17B10CXCR4SIGMAR1 | |
| SCHEMBL1904154 | 0.72 | POLB (0.48) | SMN1; SMN2POLBHSD17B10CXCR4SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023126969-A1 | ORAL FILMS OF ANIT-PARASITIC DRUGS | LAURUS LABS LIMITED (IN) | 2023-07-06 | — | — | WO | disclosed |
| CN-111771885-B | Pest control composition comprising novel iminopyridine derivatives | 株式会社MMAG | 2022-05-17 | — | — | CN | disclosed |
| EP-3694489-A2 | METHODS AND COMPOSITIONS FOR TOPICAL DELIVERY | Illustris Pharmaceuticals, Inc. (US) | 2020-08-19 | — | — | EP | disclosed |
| CN-110256336-A | Nitogen-contained heterocycle derivant with 2- imino group and the pest control agent comprising it | 明治制果药业株式会社 | 2019-09-20 | — | — | CN | disclosed |
| CN-109705032-A | Nitogen-contained heterocycle derivant with 2- imino group and the pest control agent comprising it | 明治制果药业株式会社 | 2019-05-03 | — | — | CN | disclosed |
| WO-2019075263-A2 | METHODS AND COMPOSITIONS FOR TOPICAL DELIVERY | ILLUSTRIS PHARMACEUTICALS, INC. (US) | 2019-04-18 | — | — | WO | disclosed |
| US-20190105261-A1 | METHODS AND COMPOSITIONS FOR TOPICAL DELIVERY | ILLUSTRIS PHARMACEUTICALS, INC. | 2019-04-11 | — | — | US | disclosed |
| EP-3442488-A1 | COMPOSITIONS FOR TOPICAL APPLICATION OF COMPOUNDS | Illustris Pharmaceuticals, Inc. (US) | 2019-02-20 | — | — | EP | disclosed |
| US-20190008795-A1 | COMPOSITIONS FOR TOPICAL APPLICATION OF COMPOUNDS | ILLUSTRIS PHARMACEUTICALS, INC. | 2019-01-10 | — | — | US | disclosed |
| US-20180042233-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE HAVING 2-IMINO GROUP AND PEST CONTROL AGENT INCLUDING THE SAME | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2018-02-15 | — | — | US | disclosed |
| WO-2017180788-A1 | COMPOSITIONS FOR TOPICAL APPLICATION OF COMPOUNDS | ILLUSTRIS PHARMACEUTICALS, INC. (US) | 2017-10-19 | — | — | WO | disclosed |
| US-20170290778-A1 | COMPOSITIONS FOR TOPICAL APPLICATION OF COMPOUNDS | ILLUSTRIS PHARMACEUTICALS, INC. | 2017-10-12 | — | — | US | disclosed |
| EP-2634174-B1 | Nitrogen-containing heterocyclic derivate having 2-imino group and pest control agent including the same | MEIJI SEIKA PHARMA CO LTD (JP) | 2017-05-17 | — | — | EP | disclosed |
| US-20150005347-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE HAVING 2-IMINO GROUP AND PEST CONTROL AGENT INCLUDING THE SAME | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2015-01-01 | — | — | US | disclosed |
| CN-104220424-A | Nitrogen-containing heterocyclic derivative having 2-imino group and pest control agent comprising the same | MEIJI SEIKA PHARMA CO LTD | 2014-12-17 | — | — | CN | disclosed |
| WO-2013129692-A2 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE HAVING 2-IMINO GROUP AND PEST CONTROL AGENT INCLUDING THE SAME | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2013-09-06 | — | — | WO | disclosed |
| EP-2634174-A2 | Nitrogen-containing hetercyclic derivate having 2-imino group and pest control agent including the same | Meiji Seika Pharma Co., Ltd. (JP) | 2013-09-04 | — | — | EP | disclosed |
| CN-85109721-A | Preparation has the ectoparasite of the no disease homoiothermic animal of control and the method for endoparasite compositions | — | 1987-07-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180042233-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE HAVING 2-IMINO GROUP AND PEST CONTROL AGENT INCLUDING THE SAME | CBR1, CBR3, NIT2 | SMN1; SMN2 2174/4885POLB 3786/4885HSD17B10 1105/4885 |
| US-20150005347-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE HAVING 2-IMINO GROUP AND PEST CONTROL AGENT INCLUDING THE SAME | CBR1, CBR3, NIT2 | SMN1; SMN2 2174/4885POLB 3786/4885HSD17B10 1105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.